PLUS1
0.35
-0.0201 (-5.43%)
-0.0201 (-5.43%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 545,981 |
|
|||||
| News | (1) | ||||||
| Day High | 0.3799 | Low High |
|||||
| Day Low | 0.341 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0201 | -5.43% | 0.35 | 19:56:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.361 | 0.341 | 0.3799 | 0.3455 | 0.3701 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 738 | 545,981 | $ 0.3560029 | $ 194,371 | - | 0.25 - 2.05 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:56:15 | formt | 1,108 | $ 0.35 | USD |
Period:
Draw Mode:
Marker Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 29.26M | 83.60M | 58.84M | $ 1.24M | $ - | -0.56 | -0.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 400.00k | 21.70% |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.4599 | 0.4599 | 0.341 | 0.3780656 | 582,551 | -0.1099 | -23.9% |
| 1 Month | 0.3465 | 0.66 | 0.2975 | 0.5193699 | 4,884,757 | 0.0035 | 1.01% |
| 3 Months | 0.3046 | 0.66 | 0.25 | 0.4993227 | 1,900,338 | 0.0454 | 14.9% |
| 6 Months | 0.4368 | 0.66 | 0.25 | 0.4820652 | 1,086,080 | -0.0868 | -19.87% |
| 1 Year | 1.74 | 2.05 | 0.25 | 0.7287201 | 840,402 | -1.39 | -79.89% |
| 3 Years | 5.61 | 6.54 | 0.25 | 1.93 | 853,867 | -5.26 | -93.76% |
| 5 Years | 10.01 | 10.25 | 0.25 | 2.42 | 758,173 | -9.66 | -96.5% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |
